These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29078273)

  • 1. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.
    Nakamura M; Zhang Y; Yang Y; Sonmez C; Zheng W; Huang G; Seki T; Iwamoto H; Ding B; Yin L; Foukakis T; Hatschek T; Li X; Hosaka K; Li J; Yu G; Wang X; Liu Y; Cao Y
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9635-E9644. PubMed ID: 29078273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic Therapy in Colorectal Cancer.
    Mody K; Baldeo C; Bekaii-Saab T
    Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.
    Tankiewicz-Kwedlo A; Hermanowicz J; Surażynski A; Rożkiewicz D; Pryczynicz A; Domaniewski T; Pawlak K; Kemona A; Pawlak D
    Mol Cell Biochem; 2016 Oct; 421(1-2):1-18. PubMed ID: 27543111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers.
    Amerizadeh F; Khazaei M; Maftouh M; Mardani R; Bahrami A
    Curr Pharm Des; 2018; 24(39):4668-4674. PubMed ID: 30636586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous erythropoietin and erythropoietin receptors in colorectal cancer; can we answer the questions?
    Čubranić A; Dobrila-Dintinjana R; Redžović A; Dintinjana M; Petranović D; Golčić M
    Med Hypotheses; 2016 Nov; 96():16-19. PubMed ID: 27959268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mystery Story about Erythropoietin (Epo) and Erythropoietin Receptor (EpoR) are Disguised?
    Cubranić A; Redzovic A; Dobrila-Dintinjana R; Vukelić J; Dintinjana M
    Hepatogastroenterology; 2015 May; 62(139):585-9. PubMed ID: 26897933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
    Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
    Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer.
    Li G; Zheng J; Xu B; Ling J; Qiu W; Wang Y
    Biomed Pharmacother; 2017 Jan; 85():418-424. PubMed ID: 27887848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.
    Ribatti D; Poliani PL; Longo V; Mangieri D; Nico B; Vacca A
    Histopathology; 2007 Apr; 50(5):636-41. PubMed ID: 17394500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
    Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma.
    Ribatti D; Marzullo A; Gentile A; Longo V; Nico B; Vacca A; Dammacco F
    Histopathology; 2007 Apr; 50(5):591-6. PubMed ID: 17394495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor and antiangiogenic activity of Schisandra chinensis polysaccharide in a renal cell carcinoma model.
    Qu HM; Liu SJ; Zhang CY
    Int J Biol Macromol; 2014 May; 66():52-6. PubMed ID: 24556120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.